CardioVascular BioTherapeutics (fka CVBT)

[walhall]

How zombie companies like Venturis Therapeutics die

Venturis Therapeutics (formerly Cardiovascular Biotherapeutics or CVBT) has for all practical purposes been dead since 2008. But like a good zombie company, it has continued onwards pointlessly for another 13 years, trying to give every impression of viability where there is none. Zzombie….zzzombie….zzzzzzombie…….zzzzzzzzzzzzz

But even zombie companies like Venturis Therapeutics eventually die. And that death for Venturis is at hand, now that Venturis has suffered a crushing 7-figure judgment it reportedly can’t pay. Further, Venturis is facing a winning adversary that is rumored to be planning very aggressive collection efforts. Once the final judgment amount is announced by the judge arbitrator, the collection effort is likely to immediately commence.

The only question unclear to me is whether or not Venturis’s death will come from involuntary bankruptcy and liquidation, or if Venturis will file for bankruptcy itself in the onslaught of collection activities and then be liquidated (there is no revenue stream here, so liquidation is certain). One fact is clear to me: Venturis will not be able to pay the judgment. The company has been insolvent for over a decade, and according to a particular insider who left the company and spoke candidly with a shareholder who reached out to him/her, Venturis/CVBT has been out of cash for years (i.e. illiquid) and is unable to advance on anything meaningful or costly (patents are cheap, and in this case, pointless). All the absurd chatter here indicating that Venturis Therapeutics or CVBT has raised $10 million, $150 million, $2 billion, or whatever fictional number suits the moment, based on valuations that exceed Apple’s or whatever nonsense is being spouted, is pure fantasy with a strong alcoholic delusional component. Venturis has provided zero evidence that any of it has ever happened—-because it didn’t in my opinion. Indeed, CFO Robert Schleizer said at one of the annual shareholder meetings that the company had received a qualified audit from its auditors with a going concern disclaimer. Do you know what that’s called in accounting circles? The death spiral. Companies rarely recover from it. And this one won’t.

So long, farewell, auf wiedersehen, goodbye...

For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155716827

And to hear more from a Venturis insider who spilled the beans:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155941891